Citi's Geoff Meacham on Eli Lilly's stock climbing as weight loss pill clears latest trial

Switching gears, Eli Lily surging almost 6%. It led the S&P 500 today. Their obesity pill cleared yet another late stage trial.Patients with type 2 diabetes and obesity losing an average 10 a.5% of their body weight after 72 weeks is on the highest dose. For more on what may come next, city research managing director Jeff Meechum joining us now. Jeff, great to have you on the show.What did these results mean for Lily. >> Awesome. Thanks for having me, Brian.Um, yes. So, the results here are derisking from t ...